Board Appointments

Proteome Sciences PLC
23 July 2002



                             PROTEOME SCIENCES plc


                                 PRESS RELEASE

23rd July, 2002


 PROTEOME SCIENCES ANNOUNCES TWO BOARD APPOINTMENTS: DR. WOLFGANG SCHULLER AS A
         NON-EXECUTIVE DIRECTOR AND JAMES GREEN AS COMMERCIAL DIRECTOR

Proteome Sciences plc (Proteome Sciences), the AIM listed proteomics and
modification of gene expression company, is pleased to announce that Dr.
Wolfgang (Martin Herbert Helmut) Schuller, age 49, has today been appointed to
the Board as a non-executive director and that Alfred James Green, age 54, has
today been appointed to the Board as Commercial Director.

Dr. Schuller is currently CEO of Aventis Research and Technologies GmbH & Co KG
in Frankfurt. He began his career at Hoechst AG in 1985 and holds degrees in
business administration and engineering. He has held a wide variety of finance
and management positions in Germany and internationally.

At the time of his appointment, Dr. Schuller commented :

'I am pleased to be invited on to the Board of Proteome Sciences as a
non-executive director.

By acquiring the proteomics division of Xzillion from Aventis Research and
Technologies, Proteome Sciences has now been able to extend its critical mass to
combine high out-put disease proteomics with high through-put processing.

The acquisition gives Proteome Sciences a complete proteomic approach to address
disease and significantly enhances its capacity to undertake strategic alliances
with major biotechnology and pharmaceutical companies.

Aventis R&T, which owns a 15.8% shareholding in Proteome Sciences, is committed
to support the commercialisation of Proteome Sciences' outstanding proteomic
capabilities in disease both internally for its own purposes and externally in
life sciences for its applications in diagnostics, drug discovery and
development.'

Mr Green was a Director of Polymasc Pharmaceuticals plc until the 30th September
2001. Prior to this he held senior marketing and commercial development
positions in a number of pharmaceutical and biotechnology companies over the
past 30 years including, Beecham Pharmaceuticals, The Wellcome Foundation and
Protherics plc.



Commenting on his appointment, James Green said :

'I am delighted to have been elected to the Board of Proteome Sciences and will
be focusing on the considerable commercial development opportunities for this
exciting business and on securing significant licensing deals and further
strategic partnerships with a range of pharmaceutical, biotechnology and
diagnostic companies'.



                                    - ENDS -



Enquiries and further information:

Proteome Sciences plc

Christopher Pearce, Chief Executive           Tel: [phone]

E-mail:     [e-mail]

Web: www.proteome.co.uk

Public Relations

Ikon Associates

                Adrian Shaw              Tel: [phone]

                Paul Donkersley          Tel: [phone]

                                         Mobile: [phone]

                              E-mail:    [e-mail]






                      This information is provided by RNS
            The company news service from the London Stock Exchange